Comorbidities and risk factors associated with newly diagnosed epilepsy in the U.S. pediatric population

Ahyuda Oh1, David J Thurman2, Hyunmi Kim3

  • 1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Insights

Children with newly diagnosed epilepsy often have neurobehavioral comorbidities. Neonatal seizures strongly predict epilepsy development, and epilepsy with risk factors increases intellectual disability risk.

Area of Science:

  • Pediatric Neurology
  • Neuroscience
  • Public Health

Background:

  • Neurobehavioral comorbidities are linked to epilepsy etiology, the condition itself, and antiepileptic drug side effects.
  • Understanding these links is crucial for managing epilepsy in children.

Purpose of the Study:

  • To examine the relationship between neurobehavioral comorbidities and potential risk factors in children with newly diagnosed epilepsy.
  • To identify independent predictors for epilepsy development in pediatric populations.

Main Methods:

  • Retrospective analysis of over 6 million children (≤18 years) using commercial claims data (2009-2013).
  • Defined newly diagnosed epilepsy based on ICD-9-CM codes and antiepileptic drug prescriptions.
  • Measured 12 neurobehavioral comorbidities and 11 putative epilepsy risk factors.

Main Results:

  • Newly diagnosed epilepsy identified in 7,654 children (125 per 100,000).
  • Neurobehavioral comorbidities were significantly more prevalent in children with epilepsy (60%) versus those without (23%).
  • Neonatal seizures showed the strongest independent association with epilepsy development (OR=29.8).
  • Children with both epilepsy and risk factors had a higher likelihood of intellectual disabilities (OR=13.4).

Conclusions:

  • Neurobehavioral comorbidities are highly prevalent in children with newly diagnosed epilepsy.
  • Neonatal seizures are a significant risk factor for developing epilepsy in children.
  • Epilepsy in children with risk factors is strongly associated with intellectual disabilities, suggesting shared pathophysiology.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
844
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K